Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10317429 | 0.99 | SMN1; SMN2 (0.60) | SMN1; SMN2RECQLACHEALDH1A1KDM4E | |
| SCHEMBL3709310 | 0.88 | RECQL (0.70) | SMN1; SMN2RECQLACHEALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL3706762 | 0.86 | RECQL (0.68) | SMN1; SMN2RECQLACHEALDH1A1KDM4E | |
| SCHEMBL2717435 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16641754 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL21044023 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8033956 | 0.86 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL9058966 | 0.85 | ACHE (0.60) | SMN1; SMN2RECQLACHEALDH1A1KDM4E | |
| SCHEMBL10566682 | 0.85 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6963387 | 0.85 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071286-A1 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071286-A1 | NOVEL PREPARATION PROCESS | RPLP1, RPLP2, CYP1B1 | SMN1; SMN2 941/4885RECQL 487/4885ACHE 2237/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | SMN1; SMN2 4092/4885RECQL 665/4885ACHE 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.